Related references
Note: Only part of the references are listed.Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody
Ryota Shibaki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece
Argyris Tzouvelekis et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2020)
Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
Beatriz Ballester et al.
Oncotarget (2020)
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Beatriz Ballester et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer
Joseph A. Pinto et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
Shohei Hamada et al.
BMC PULMONARY MEDICINE (2019)
The Oncogene ECT2 Contributes to a Hyperplastic, Proliferative Lung Epithelial Cell Phenotype in Idiopathic Pulmonary Fibrosis
Henrik M. Ulke et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study
Hongseok Yoo et al.
BMC PULMONARY MEDICINE (2019)
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
JanWillem Duitman et al.
JOURNAL OF CLINICAL MEDICINE (2019)
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
Maria Colombino et al.
BMC PULMONARY MEDICINE (2019)
Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest
Kenichiro Ishii et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debate
C. Arnold Spek et al.
ERJ OPEN RESEARCH (2019)
Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
Carlo Putzu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Prevalence of lung cancer in patients with interstitial lung disease is higher than in those with chronic obstructive pulmonary disease
Hye In Jung et al.
MEDICINE (2018)
Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study
Won-Il Choi et al.
CANCER RESEARCH AND TREATMENT (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients
Alessandro Giuseppe Fois et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis
Yan Liu et al.
CLINICAL RESPIRATORY JOURNAL (2018)
Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review
Alessandro G. Fois et al.
RESPIRATORY RESEARCH (2018)
Role of immune-checkpoint inhibitors in lung cancer
Prantesh Jain et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Miguel Quintela-Fandino et al.
CLINICAL CANCER RESEARCH (2017)
Nintedanib in ovarian cancer
Saira Khalique et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
De-novo and acquired resistance to immune checkpoint targeting
Nicholas L. Syn et al.
LANCET ONCOLOGY (2017)
Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer
Ayako Fujiwara et al.
LUNG CANCER (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells
Jun An et al.
ONCOTARGET (2017)
Pirfenidone normalizes the tumor microenvironment to improve chemotherapy
Christiana Polydorou et al.
ONCOTARGET (2017)
Idiopathic pulmonary fibrosis
Fernando J. Martinez et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses
Alice Guyard et al.
RESPIRATORY RESEARCH (2017)
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)
Youjin Kim et al.
CANCER (2017)
The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
Melanie Mediavilla-Varela et al.
BMC CANCER (2016)
Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment
Takuji Okusaka et al.
CANCER SCIENCE (2016)
Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer
Yasunori Enomoto et al.
LUNG CANCER (2016)
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
Nasser H. Hanna et al.
LUNG CANCER (2016)
Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
Xiang Huang et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Ken Takai et al.
ONCOTARGET (2016)
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines
Xiao-Yan Bai et al.
PLOS ONE (2016)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
M. Catherine Pietanza et al.
CLINICAL CANCER RESEARCH (2015)
Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma
Panagiotis Paliogiannis et al.
MOLECULAR MEDICINE REPORTS (2015)
Ponatinib ameliorates pulmonary fibrosis by suppressing TGF-β1/Smad3 pathway
Yubei Qu et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology
Sohita Dhillon
TARGETED ONCOLOGY (2015)
Interstitial lung disease induced by alectinib (CH5424802/RO5424802)
Satoshi Ikeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Pulmonary Function and Survival in Idiopathic vs Secondary Usual Interstitial Pneumonia
Matthew J. Strand et al.
CHEST (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema
Yuji Minegishi et al.
LUNG CANCER (2014)
Tyrosine kinase signaling in fibrotic disorders Translation of basic research to human disease
Christian Beyer et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Bercin Kutluk Cenik et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Low-Dose Paclitaxel Ameliorates Pulmonary Fibrosis by Suppressing TGF-β1/Smad3 Pathway via miR-140 Upregulation
Congjie Wang et al.
PLOS ONE (2013)
Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation
Y-L Chen et al.
CELL DEATH & DISEASE (2013)
Common pathways in idiopathic pulmonary fibrosis and cancer
Carlo Vancheri
EUROPEAN RESPIRATORY REVIEW (2013)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Fatal Asymmetric Interstitial Lung Disease after Erlotinib for Lung Cancer
Shaohua Ren et al.
RESPIRATION (2012)
Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells
Keiko Hisatomi et al.
BMC PULMONARY MEDICINE (2012)
Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
Ji Hye Min et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance
Qing-feng Xiang et al.
CELLULAR ONCOLOGY (2011)
Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations
Jessica Gordon et al.
CURRENT RHEUMATOLOGY REPORTS (2011)
Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis
Soo-Jung Um et al.
CLINICAL RESPIRATORY JOURNAL (2009)
Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
Paul M. Hassoun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Superoxide scavenging activity of pirfenidone-iron complex
Yoshihiro Mitani et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis
J. H. W. Distler et al.
RHEUMATOLOGY (2008)
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
M Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis
M Selman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice
Y Aono et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Interstitial lung disease associated with drug therapy
P Camus et al.
BRITISH JOURNAL OF CANCER (2004)
Share Paper
